Business
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
- This is the second patent ruling issued today from the Court in favor of Acadia SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n- This is the second patent ruling issued today from the Court in favor of Acadia\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s Order, the Court ruled in favor of Acadia on all of the disputed claim construction points.\n\n\nIn the Order, the Court adopted Acadia’s interpretation of key disputed terms of the patent. Acadia believes that the Court’s interpretations affirm the strength of the patent. As a result of today’s order, a claims construction hearing (also referred to as a “Markman” hearing), which had been scheduled for December 19, 2023, has been cancelled by the Court. The case remains scheduled for trial in December 2024.\n\n\nThis was the second ruling issued today by the Court pertaining to Acadia’s patents covering NUPLAZID. Earlier today, in a separate litigation, the Court granted summary judgment to Acadia, confirming validity of Acadia’s ‘740 composition of matter patent.\n\n\n“We are pleased to announce a second positive ruling today from the U.S. District Court for the District of Delaware, both of which underscore the strength of our NUPLAZID patent estate, including patents running into 2038,” said Steve Davis, President and Chief Executive Officer. “Establishing claims construction is an important milestone in patent litigation. We look forward to proceeding with the remainder of our formulation patent case.”\n\n\nThe formulation patent that is the subject of today’s claims construction ruling is scheduled to expire in 2038. In addition, Acadia has a method of use patent on the 10mg tablet of NUPLAZID that runs to 2037 and a NUPLAZID composition of matter patent, which was the subject of today’s earlier ruling, that runs to 2030.\n\n\nAbout NUPLAZID® (pimavanserin)\n\n\nPimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic recept...